What you believe and what you value as an organization matters. Discover the DNA of our firm.
Get to know our teams and the stories of select staff members who share why they choose to work at Sands Capital.
Read about some of the latest events, partnerships, and business highlights from Sands Capital.
From aquaculture to semiconductors, European firms are quietly becoming global leaders in innovation, sustainability, and value creation.
In this episode of What Matters Most, Sands Capital Portfolio Manager and Sr. Research Analyst Danielle Menichella discusses the business’ journey from Taser maker to artificial intelligence-powered software developer.
Executive Managing Director and Senior Portfolio Manager Brian Christiansen discusses the importance of candor, collaboration, and entrepreneurialism in creating a culture that promotes long-term thinking.
FPT has harnessed education to drive Vietnam’s digital transformation and human-capital development.
Our philosophy is rooted in the belief that, over time, stock prices will reflect the earnings power and growth of the underlying businesses.
Our latest annual report offers a comprehensive view of how we add value through active stewardship.
Our newest strategy takes an unconstrained approach to seeking the best growth businesses outside of the U.S.
Sands Capital invests in innovative businesses across all stages of the growth spectrum
Partner
2021
RA Capital (2020 - 2021)
Boston, MA | Principal, Tools and Diagnostics
Farcast Biosciences / Mitra Biotech (2015 - 2020)
Woburn, MA | Head of Strategy, Chief Commercial Officer
RA Capital (2015)
Boston, MA | Entrepreneur in Residence
Becton Dickinson (2006 - 2014)
Franklin Lakes, NJ | VP
Serologicals / Upstate Biotechnology (2000 - 2006)
Charlottesville, VA | VP
Pratt & Whitney (1996 - 1998)
Hartford, CT | Manufacturing Engineer
University of Virginia (2000)
MBA | Darden School of Business
Boston University (1995)
BS | Mechanical Engineering
Parker is a partner on the Life Sciences Pulse strategy. He joined Sands Capital in 2021. Parker has 20 years of operational experience with life science tools, diagnostics, and device companies in a range of commercial, development, and general management roles. In those positions, he has been accountable for revenue ranging from launch up to $70 million annually, led acquisitions and integrations, and designed and executed multiple clinical trials. He has been an advisor, investor, and board member for private life science companies since 2015.
Parker received a BS in mechanical engineering from Boston University and an MBA from the UVA Darden School of Business.
Notice for non-US Investors